Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

BJ Bio Starts US Trials of Targeted IL-15 Fusion Protein in Solid Tumors

publication date: Dec 10, 2019

BJ Bioscience, a Hangzhou-San Francisco novel drug developer, announced the first patient was dosed in a US Phase I trial of BJ-001, a targeted IL-15 fusion protein aimed at solid tumors. BJ-001 is designed to target cancer cells that overexpress integrins such as αvβ3, αvβ5, and αvβ6 and stimulate immunity with IL-15. Non-small cell lung cancer, stomach cancer, and pancreatic cancer have been shown to overexpress integrin. BJ Bio says BJ-001 is the first tumor targeting IL-15 fusion protein in the world. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.